常氧和缺氧条件下氧气和抗癌药物共同输送对健康细胞和癌细胞活力的影响。
The Effect of Co-Delivery of Oxygen and Anticancer Drugs on the Viability of Healthy and Cancer Cells under Normoxic and Hypoxic Conditions.
发表日期:2024 Jul 09
作者:
Nermin Seda Kehr
来源:
MACROMOLECULAR BIOSCIENCE
摘要:
缺氧、癌症、组织损伤和酸性pH条件是相互关联的,因为慢性缺氧条件会增强癌细胞的恶性表型,导致更积极的组织破坏,而缺氧细胞依赖无氧糖酵解,导致乳酸积累。因此,必须给予氧气来支持健康细胞的功能直至新血管的形成,并增加癌组织的氧气供应,以提高抗肿瘤药物对肿瘤细胞的疗效。除了氧气供应之外,还需要依赖 pH 值的抗癌药物递送来靶向癌细胞并减少药物对健康细胞的副作用。然而,通过纳米材料同时输送 O2 和 pH 依赖性抗癌药物及其在缺氧条件下对正常细胞和癌细胞活力的影响尚未得到足够的研究。这项研究描述了一种含有氧气和抗癌药物的 pH 响应性纳米材料的合成,该材料在缺氧条件下可在 14 天内持续释放 O2,并在 30 天内实现 pH 依赖性持续释放抗癌药物。在缺氧和常氧条件下,同时给予 O2 和抗癌药物可导致正常细胞的细胞存活率高于癌细胞。© 2024 作者。高分子生物科学由 Wiley‐VCH GmbH 出版。
Hypoxia, cancer, tissue damage, and acidic pH conditions are interrelated, as chronic hypoxic conditions enhance the malignant phenotype of cancer cells, causing more aggressive tissue destruction, and hypoxic cells rely on anaerobic glycolysis, leading to the accumulation of lactic acid. Therefore, the administration of oxygen is necessary to support the functions of healthy cells until the formation of new blood vessels and to increase the oxygen supply to cancerous tissues to improve the efficacy of antitumor drugs on tumor cells. In addition to O2 supply, pH-dependent delivery of anticancer drugs is desired to target cancer cells and reduce drug side effects on healthy cells. However, the simultaneous delivery of O2 and pH-dependent anticancer drugs via nanomaterials and their effects on the viability of normal and cancer cells under hypoxic conditions have not been studied in sufficient numbers. This study describes the synthesis of a pH-responsive nanomaterial containing oxygen and anticancer drugs that exhibits sustained O2 release over a 14 d period under hypoxic conditions and pH-dependent sustained release of anticancer drugs over 30 d. The simultaneous administration of O2 and anticancer drugs results in higher cell survival of normal cells than that of cancer cells under hypoxic and normoxic conditions.© 2024 The Author(s). Macromolecular Bioscience published by Wiley‐VCH GmbH.